A5102728954- Diabetes Management and Research
- Diabetes Treatment and Management
- Blood Pressure and Hypertension Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Chronic Kidney Disease and Diabetes
- Metabolism, Diabetes, and Cancer
- Healthcare Regulation
- Cardiovascular Health and Disease Prevention
- Nutritional Studies and Diet
- Diet and metabolism studies
- Retinal Diseases and Treatments
- Thyroid Cancer Diagnosis and Treatment
- Pharmacology and Obesity Treatment
- Agricultural and Food Sciences
- Cardiovascular Function and Risk Factors
- Healthcare during COVID-19 Pandemic
- Dialysis and Renal Disease Management
- Pancreatic function and diabetes
- Retinal Imaging and Analysis
- Thyroid Disorders and Treatments
- Diabetes Management and Education
- Heart Rate Variability and Autonomic Control
- Health and Lifestyle Studies
- Advanced Glycation End Products research
- Fatty Acid Research and Health
Hospital de Clínicas de Porto Alegre
2013-2022
Universidade Federal do Rio Grande do Sul
2013-2022
Hospital de Clínicas
1992-2022
Hospital Moinhos de Vento
2017
Universidade Federal de São Paulo
2015
Forschungs- und Entwicklungszentrum Fachhochschule Kiel (Germany)
2014
Universitäts Hautklinik Kiel
2014
University Hospital Schleswig-Holstein
2014
University of Lübeck
2014
University of New Orleans
2014
To evaluate the efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, compared with sitagliptin in subjects type diabetes inadequately controlled metformin plus sulfonylurea.
OBJECTIVE This 24-week trial assessed the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes inadequate glycemic control metformin alone. RESEARCH DESIGN AND METHODS was a randomized, double-blind, placebo-controlled study (2.5, 5, or 10 mg once daily) placebo plus stable dose (1,500–2,500 mg) 743 (A1C ≥7.0 ≤10.0%). Efficacy analyses were performed using an ANCOVA model last observation carried forward methodology on primary (A1C) secondary (fasting plasma...
GLP-1 receptor agonists may provide an alternative to prandial insulin for advancing basal therapy. Harmony 6 was a randomized, open-label, active-controlled trial testing once-weekly albiglutide vs. thrice-daily lispro as add-on titrated once-daily glargine.Patients taking (with or without oral agents) with HbA1c 7-10.5% (53-91 mmol/mol) entered glargine standardization period, followed by randomization albiglutide, 30 mg weekly (n = 282), subsequently uptitrated 50 mg, if necessary, 281)...
The single-nucleotide polymorphism A/G in the type 2 deiodinase (D2) gene predicts a threonine (Thr) to alanine (Ala) substitution at codon 92 (D2 Thr92Ala) and is associated with insulin resistance obese patients. Here, this association was investigated 183 patients diabetes mellitus, using homeostasis model assessment. median fasting plasma Ala/Ala individuals significantly higher than Ala/Thr or Thr/Thr genotypes (19.6 vs. 12.0 14.8 mIU/ml, respectively; P = 0.004). Assuming recessive...
OBJECTIVE To assess the performance of measurements urinary albumin concentration (UAC) and albumin:creatinine ratio (UACR) in a diurnal random urine specimen (RUS) for screening diabetic nephropathy. RESEARCH DESIGN AND METHODS A total 95 ambulatory NIDDM patients (49 women, ages 40–75 years) collected 123 RUSs during morning after completing timed 24-h collection. Albumin was measured by immunoturbidimetry. According to excretion rate (UAER) collection (criterion standard), samples were...
Abstract Aims To investigate the association of features metabolic syndrome with prevalence chronic complications. Methods A cross‐sectional study was conducted 548 patients Type 2 diabetes mellitus (DM). Metabolic diagnosed in presence at least two following: hypertension, dyslipidaemia, obesity, and microalbuminuria. Results Patients (85%) had a higher peripheral vascular disease (PVD) (35% vs. 18%), retinopathy (44% 20%), distal sensory neuropathy (DSN) 24%), micro‐ macroalbuminuria (38%...
To assess the efficacy and safety of alogliptin added to insulin in patients with type 2 diabetes inadequately controlled alone or combined metformin.In this 26-week, double-blind, placebo-controlled study, 390 were randomized receive 12.5 mg (n = 131), 25 129) placebo 130) once daily, as add-on stable therapy without metformin. The primary endpoint was change haemoglobin A(1C) (HbA(1C)) at week 26.At 26, mean HbA(1C) changes from baseline value 9.3% significantly greater for (-0.63 +/-...
A diet rich in fibre seems to protect against the metabolic syndrome (MetS), but there is scarce information about role of intake patients with MetS and diabetes. The aim present study was evaluate effects soluble from partially hydrolysed guar gum (PHGG) on cardiovascular risk factors type 2 In randomised controlled clinical trial, forty-four diabetes (males 38·6 %, age 62 ( sd 9) years, duration 14·2 9·6) years) underwent clinical, laboratory dietary evaluations at baseline, 4 6 weeks. All...
Data on the potential beneficial effects of combining diet and exercise blood pressure ( BP ) are still scarce. A 4‐week randomized controlled clinical trial was undertaken in 40 hypertensive patients with type 2 diabetes uncontrolled office daytime ambulatory monitoring ABPM ). Patients were assigned to follow a Dietary Approaches Stop Hypertension (DASH) associated advice increase walking using pedometer (intervention group) or based American Diabetes Association recommendations (control...
Diabetes e alterações da tolerância à glicose são freqüentes na população adulta estão associados a um aumento mortalidade por doença cardiovascular complicações microvasculares. O diagnóstico destas situações deve ser feito precocemente, utilizando métodos sensíveis acurados, já que mudanças no estilo de vida correção hiperglicemia podem retardar o aparecimento do diabetes ou suas complicações. teste oral é método referência, considerando-se presença diminuída quando plasmática 2h após...
We sought to evaluate the effects of muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor (PPAR) activator within new glitazar class, on hyperglycemia and lipid abnormalities.A double-blind, randomized, controlled trial was performed in 1,159 patients with type 2 diabetes inadequately metformin. Patients received once-daily doses either 5 mg muraglitazar or 30 pioglitazone for total 24 weeks addition open-label were continued double-blind fashion an additional 26...